Pura Vida Investments, Llc - Apr 14, 2022 Form 4/A - Amendment Insider Report for Oncocyte Corp (OCX)

Role: 10%+ Owner
Signature: /s/ Efrem Kamen, Managing Member of Pura Vida Investments, LLC
Stock symbol: OCX
Transactions as of: Apr 14, 2022
Transactions value $: $250,350
Form type: 4/A - Amendment
Date filed: 6/28/2022, 07:46 PM
Date Of Original Report: Apr 18, 2022
Previous filing: Sep 17, 2021
Next filing: Jun 28, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCX	Common Stock	Purchase	$37.8K	+30.8K	+0.42%	$1.23	7.38M	Apr 14, 2022	By Pura Vida Master Fund, Ltd.	F1, F2, F3, F4
transaction	OCX	Common Stock	Purchase	$116K	+92.4K	+1.25%	$1.26	7.47M	Apr 14, 2022	By Pura Vida Master Fund, Ltd.	F1, F3, F4, F5
transaction	OCX	Common Stock	Purchase	$23.6K	+19.2K	+0.23%	$1.23	8.48M	Apr 14, 2022	By the Managed Accounts.	F1, F2, F3, F4
transaction	OCX	Common Stock	Purchase	$72.6K	+57.6K	+0.68%	$1.26	8.53M	Apr 14, 2022	By the Managed Accounts.	F1, F3, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Aggregate number of shares purchased on the same date at difference prices.
F2	Represents the weighted-average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.19 to $1.27, inclusive, per share. Full information regarding the number of shares purchased at each price shall be provided to the Securities and Exchange Commission staff (the "Staff"), Issuer or any security holder, upon request.
F3	Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," and together with the Pura Vida Master Fund, collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI.
F4	By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any.
F5	Represents the weighted-average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.235 to $1.305, inclusive, per share. Full information regarding the number of shares purchased at each price shall be provided to the Staff, Issuer or any security holder, upon request.

Remarks:

This Form 4/A is being filed to provide the weighted-average purchase prices of the transactions reported herein, which were inadvertently omitted in the Form 4.